CRMevidence™

01 / Our capabilities

Market Intelligence & Evidence

International healthcare companies need to assess demand, clinical practice, purchasing structures and competitive alternatives before committing resources to Mexico. Evidence that supports a product in one country may not answer the questions of Mexican decision-makers.

Armando Romero and a colleague review market data together.
AI-assisted illustration featuring Armando Romero in a fictional meeting.
Mexico’s 2026 population pyramid by five-year age group, with men on the left and women on the right.
Mexico’s 2026 age structure as shown in the CRMevidence company presentation, slide 4. The slide cites UN World Population Prospects 2024.

Market assessment roadmap

An example of how a project can prepare for market entry in Mexico.

  1. Define the market

    Narrow down the indication, patient groups, demand and purchasing channels in Mexico.

    Potential outputMarket overview and stakeholder map

  2. Assess the evidence

    Review clinical data, local comparators and health economic assumptions.

    Potential outputOverview of evidence and data gaps

  3. Prioritize opportunities

    Compare segments and positioning options by attractiveness, feasibility and uncertainty.

    Potential outputPriority segments and positioning hypotheses

  4. Prepare the decision

    Bring together assumptions, open questions and next steps for market entry.

    Potential outputDecision brief with next steps

The challenge

International healthcare companies need to assess demand, clinical practice, purchasing structures and competitive alternatives before committing resources to Mexico. Evidence that supports a product in one country may not answer the questions of Mexican decision-makers.

How CRMevidence could support

Define the target market and relevant patient groups; map public and private stakeholders; assess epidemiological and market data; review published clinical evidence and health-economic assumptions; identify evidence gaps and prioritise further research.

Potential project outputs

A market landscape, stakeholder map, evidence-gap assessment, positioning hypotheses and a prioritised market-entry decision framework.

Important qualification

Any health technology assessment or economic model must use appropriate data and transparent assumptions. The availability and quality of local evidence require project-specific validation.

Additional detail from CRMevidence corporate profile (November 2026)

The corporate profile identifies market mapping, institutional demand, clinical and economic evidence reviews, comparator selection, budget-impact modelling, procurement monitoring, tender specifications and competitor benchmarking as potential workstreams.

Proposed service scope. Subject to confirmation by CRMevidence.